This site is intended for health professionals only
Monday 27 May 2019
Share |

Topic: Hepatic disorders

April 10, 2019
Modelling study shows that up to 43% of the world’s future hepatitis C infections could be prevented if transmission among people who inject drugs was reduced

Stepping up efforts to prevent transmission of hepatitis C among people who inject drugs, could reduce future infections by 43% globally, according to a study by researchers at the University of Bristol published in the Lancet Gastroenterology and Hepatology.1
 

February 22, 2018
Vosevi® is the first single tablet regimen for patients who have previously failed therapy with direct-acting antivirals

Gilead Sciences has welcomed the Technology Appraisal Guidance (TAG) issued by the National Institute for Health and Care Excellence (NICE), which recommends Vosevi® (sofosbuvir 400mg/velpatasvir 100mg/voxilaprevir 100mg; SOF/VEL/VOX).1

 

August 19, 2016
NICE draft guidance does not recommend Nexavar® (sorafenib) for the treatment of patients with advanced hepatocellular carcinoma who have failed or are unsuitable for surgical or loco-regional therapies

The National Institute for Health and Care Excellence (NICE) has released an Appraisal Consultation Document (ACD) with draft guidance not recommending Nexavar® (sorafenib) for the treatment of patients with advanced hepatocellular carcinoma (HCC) who have failed or are unsuitable for surgical or loco-regional therapies.1
 

January 19, 2016
Swedish Orphan Biovitrum AB (publ) (Sobi) announced that the European Patent Office (EPO) has decided to grant a European patent for the Orfadin® (nitisinone) oral suspension formulation

Swedish Orphan Biovitrum AB (publ) (Sobi) announced that the European Patent Office (EPO) has decided to grant a European patent for the Orfadin® (nitisinone) oral suspension formulation, which was approved by the European Commission for the treatment of Hereditary Tyrosinaemia type-1 (HT-1) in 2015. HT-1 is a rare genetic disease that affects infants and children. It is progressive and may result in liver and kidney complications and can be fatal if untreated.

 

November 19, 2015
Investigational HCV regimen with ABT-493 and ABT-530 evaluating a pan-genotypic, once-daily treatment option with shorter duration of therapy
October 16, 2015
VIEKIRAX + EXVIERA confirmed as cost effective treatment for adults with genotype 1 chronic hepatitis C virus (HCV) infection, including those with HIV/HCV co-infection, in NICE Final Appraisal Determination (FAD)

An estimated 214,000 people in the UK are chronically infected with hepatitis C (1), of which only an estimated 3% receive treatment in England each year (2).

 

September 14, 2015
Daklinza in combination with sofosbuvir is the first 12-week all-oral therapy for genotype 3 patients without cirrhosis in Europe

Bristol-Myers Squibb Company announced that the European Commission has approved an updated label for Daklinza for the treatment of genotype 3 chronic hepatitis C (HCV). The update allows the use of Daklinza in combination with sofosbuvir for 12 weeks in patients without cirrhosis in all 28 Member States of the European Union, and marks the first time these patients with genotype 3 HCV have a once-daily, all-oral treatment regimen of this shorter duration.

 

June 10, 2015
More than 200,000 people in the UK are chronically infected with hepatitis C, (1) of which only an estimated 3% are treated each year, despite the advent of treatments that can offer viral elimination. (1)

More than 200,000 people in the UK are chronically infected with hepatitis C, (1) of which only an estimated 3% are treated each year, despite the advent of treatments that can offer viral elimination. (1)

May 28, 2015
A feared complication of haematopoietic stem cell transplantation is veno-occlusive disease, a serious condition associated with multi-organ failure and mortality rates ranging up to 98% for severe disease in adults

 

May 6, 2015
Swedish Orphan Biovitrum AB (publ) (Sobi) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the oral suspension formulation and the 20mg capsule of Orfadin (nitisinone) for the treatment of hereditary tyrosinaemia type-1 (HT-1). HT-1 is a rare genetic disease that affects infants and children; it is progressive in nature, may result in liver and kidney failure and can be fatal if untreated.

Swedish Orphan Biovitrum AB (publ) (Sobi) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the oral suspension formulation and the 20mg capsule of Orfadin (nitisinone) for the treatment of hereditary tyrosinaemia type-1 (HT-1). HT-1 is a rare genetic disease that affects infants and children; it is progressive in nature, may result in liver and kidney failure and can be fatal if untreated.  

February 16, 2015
New drugs, such as simeprevir, sofosbuvir and daclatasvir, have the advantage of once-daily dosing, fewer adverse effects and efficacy against multiple hepatitis C virus genotypes

 

January 16, 2015
Janssen welcomes the Final Appraisal Determination (FAD) from the National Institute for Health and Care Excellence (NICE) published that recommends the use of Olysio™ (simeprevir), for the treatment of chronic hepatitis C genotype 1 and 4 infection in combination with other medicines to treat HCV infection.

Janssen welcomes the Final Appraisal Determination (FAD) from the National Institute for Health and Care Excellence (NICE) published that recommends the use of Olysio™ (simeprevir), for the treatment of chronic hepatitis C genotype 1 and 4 infection in combination with other medicines to treat HCV infection. (1)

January 16, 2015
A new hepatitis C medicine, called simeprevir, is now available that the NHS in England will only pay for if patients successfully clear the virus. The ‘pay if you clear’ reimbursement scheme, agreed with NHS England, refunds the cost of simeprevir for patients who do not successfully clear the virus after 12 weeks.

A new hepatitis C medicine, called simeprevir, is now available that the NHS in England will only pay for if patients successfully clear the virus. The ‘pay if you clear’ reimbursement scheme, agreed with NHS England, refunds the cost of simeprevir for patients who do not successfully clear the virus after 12 weeks.

August 28, 2014
Bristol-Myers Squibb has announced that the European Commission has approved Daklinza for use in combination with other medicinal products across genotypes 1, 2, 3 and 4 for the treatment of chronic hepatitis C virus infection in adults.

Bristol-Myers Squibb has announced that the European Commission has approved Daklinza (daclatasvir), a potent, pan-genotypic NS5A replication complex inhibitor (in vitro), for use in combination with other medicinal products across genotypes 1, 2, 3 and 4 for the treatment of chronic hepatitis C virus (HCV) infection in adults.

August 15, 2014
Sovaldi (sofosbuvir) should be made available, as part of a combination treatment regimen, to treat the majority of adult patients with chronic hepatitis C in England and Wales.

 

June 10, 2014
Jazz Pharmaceuticals has announced that the Scottish Medicines Consortium (SMC) has accepted Defitelio (defibrotide) for use within NHS Scotland.

 Jazz Pharmaceuticals has announced that the Scottish Medicines Consortium (SMC) has accepted Defitelio® (defibrotide) for use within NHS Scotland.(1)

You are leaving www.nursinginpractice.com

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?

Close

Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.


GET INVOLVED: SIGN OUR E-PETITION

Close

Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher




http://www.facebook.com/NursinginPracticeMagazine